Patient Note — 55992

progress_notes_55992_1_deid.txt

← Back to all patients Run PA Decision for this patient →

Demographics & Encounter

Patient ID55992 (PHI redacted)
Age / Gender62 / Male
Date of Service2026-02-13
ProviderNone
FacilityPOTOMAC UROLOGY CENTER - Woodbridge
PayerTricare East
Reason1. 3m Testopel 10

Diagnoses

E29.1 Testicular hypofunction

Medications

Testopel(Testosterone) Mounjaro(Tirzepatide) 7.5 MG/0.5ML Solution Pen-injector as directed Subcutaneous CeleBREX Metoprolol Succinate ER metFORMIN HCl Progress Note: [PROVIDER_NAME], PA 02/13/2026 Note generated by eClinicalWorks EMR/PM Software (www.eClinicalWorks.com) Generated for Printing/Faxing/eTransmitting on: 04/21/2026 04:42 AM EDT 1/4 4/21/26, 1:42 AM Print Preview [PATIENT_NAME] DOB: [DOB] (62 yo M) Acc No. [ACCOUNT_ID] DOS: 02/13/2026

Past Medical History

  • Arthritis
  • Diabetes
  • Low Testosterone

Clinical Summary (HPI)

Low Testosterone: 62yM w/ hx of low testosterone presents for Testopel QTY (10). The patient is overall doing well on Testopel QTY (10+2) every 3 months. He denies any drop-off effect. He has recently donated blood. - - - - - - -- The patient's previous workup history is listed below: Testosterone: 340 (February 2026); 360 (November 2025); 304 (May 2025); 469 (Jan 2025); 422 (Oct 2024); 410 (July 2024); 326 (April 2024); 266 (Jan 2024); 267 (Sept 2023); 238 (June 2023); 164 (Mar 2023); 355 (Dec 2022); 228 (11/22); 265 (7/22); 1030 [5/11/22]; 275 [Oct. 2021], 415 [Apr 2021], 236 [Sep 2020] FT-Calc: 66.6 (May 2025) HCT: 46 (February 2026); 51 (November 2025); 47 (May 2025); 52 (Jan 2025); 50 (Oct 2024); 47 (Jan 2024); 47 (Sept 2023); 47 (Mar 2023); 52 [H] (5/11/22); 50 (10/21) Hepatic: WNL (November 2025); WNL (July [ACCOUNT_ID]); WNL (Jan 2024); ALT 62 (Sept 2023); WNL (5/22) PSA: 0.61 (February 2026); 1.97 (November 2025); 0.60 (Jan 2025); 0.54 (July 2024); 0.47 (Jan 2024); 0.45 (Sept 2023); 0.33 (Mar 2023); 0.44 [May 2022]; 0.28 [Oct. 2021], 0.7 [Sep 2020]. Previous Treatments Medication Gel/cream Current Therapy Testopel? Yes # Testopel placed at last visit 10 + 2 Tpellets Date of last Testopel insertion 04/29/2024

Raw Note (de-identified preview)

4/21/26, 1:42 AM Print Preview [PATIENT_NAME] DOB: [DOB] (62 yo M) Acc No. [ACCOUNT_ID] DOS: 02/13/2026 [PATIENT_NAME] 62 Y old Male, DOB: [DOB] Account: [ACCOUNT_ID]: [ACCOUNT_ID] [ADDRESS], FREDERICKSBURG, VA-[ACCOUNT_ID] Home: [PHONE] Guarantor: [PATIENT_NAME] Insurance: Tricare East PGBA Referring: [PROVIDER_NAME] Appointment Facility: POTOMAC UROLOGY CENTER - Woodbridge Structured Data: How did you hear about us? : Other; Patient's temperature : 97.8; : 11/14/2022 02/13/2026 Testopel: [PROVIDER_NAME], PA Reason for Appointment 1. 3m Testopel 10 History of Present Illness Low Testosterone: 62yM w/ hx of low testosterone presents for Testopel QTY (10). The patient is overall doing well on Testopel QTY (10+2) every 3 months. He denies any drop-off effect. He has recently donated blood. - - - - - - -- The patient's previous workup history is listed below: Testosterone: 340 (February 2026); 360 (November 2025); 304 (May 2025); 469 (Jan 2025); 422 (Oct 2024); 410 (July 2024); 326 (April 2024); 266 (Jan 2024); 267 (Sept 2023); 238 (June 2023); 164 (Mar 2023); 355 (Dec 2022); 228 (11/22); 265 (7/22); 1030 [5/11/22]; 275 [Oct. 2021], 415 [Apr 2021], 236 [Sep 2020] FT-Calc: 66.6 (May 2025) HCT: 46 (February 2026); 51 (November 2025); 47 (May 2025); 52 (Jan 2025); 50 (Oct 2024); 47 (Jan 2024); 47 (Sept 2023); 47 (Mar 2023); 52 [H] (5/11/22); 50 (10/21) Hepatic: WNL (November 2025); WNL (July [ACCOUNT_ID]); WNL (Jan 2024); ALT 62 (Sept 2023); WNL (5/22) PSA: 0.61 (February 2026); 1.97 (November 2025); 0.60 (Jan 2025); 0.54 (July 2024); 0.47 (Jan 2024); 0.45 (Sept 2023); 0.33 (Mar 2023); 0.44 [May 2022]; 0.28 [Oct. 2021], 0.7 [Sep 2020]. Previous Treatments Medication Gel/cream Current Therapy Testopel? Yes # Testopel placed at last visit 10 + 2 Tpellets Date of last Testopel insertion 04/29/2024 Current Medications Taking Testopel(Testosterone) 75 MG Pellet as directed Implant Mounjaro(Tirzepatide) 7.5 MG/0.5ML Solution Pen-injector as directed Subcutaneous CeleBREX 200 MG Capsule 1 capsule with food Orally Once a day Metoprolol Succinate ER 25 MG Tablet Extended Release 24 Hour Oral metFORMIN HCl 500 MG Tablet Oral Progress Note: [PROVIDER_NAME], PA 02/13/2026 Note generated by eClinicalWorks EMR/PM Software (www.eClinicalWorks.com) Generated for Printing/Faxing/eTransmitting on: 04/21/2026 04:42 AM EDT 1/4 4/21/26, 1:42 AM Print Preview [PATIENT_NAME] DOB: [DOB] (62 yo M) Acc No. [ACCOUNT_ID] DOS: 02/13/2026 Past Medical History Arthritis. Diabetes. Low Testosterone. Surgical History appendectomy 1980 L Testicle Cyst Exition Family History Father: unknown Mother: alive, arthritis, GERD, hypertension, osteoporosis, diagnosed with Hypertension Social History Smoking: no Are you a:: nonsmoker. Recreational drug use: no. Exercise: no. Caffeine: yes, frequency:5 a day. Alcohol: no Sexually active: yes. Occupation: [EMPLOYER]. Screening Allergies Penicillin Hospitalization/Major Diagnostic Procedure No Hospitalization History. Review of Systems 11 system R